Drug Profile
Df-IA2BM-Zr-89 - ImaginAb
Alternative Names: [89Zr]Df-IAB2M; IAB2M; IAB2M PSMA minibody; IAB2M PSMA PET imaging agentLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator ImaginAb Inc
- Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
- No development reported Glioma
Most Recent Events
- 25 Jun 2019 No development reported - Phase-I/II for Glioma (Diagnosis) in Japan (IV)
- 13 Feb 2017 ImaginAb completes a phase I/II trial in Glioma (Diagnosis) in Japan (IV) (UMIN000018639)
- 01 Jul 2016 ImaginAb completes a phase II trial for Prostate cancer (Diagnosis) in USA (NCT02349022)